

## Contents

Contributors	xiii
1. Physiology of erythropoiesis <i>U. Testa</i>	1
2. Biology of EPO and EPO-receptor <i>C. Lacombe and P. Mayeux</i>	67
3. The role of erythropoietin receptor expression on tumor cells <i>J. Fandrey</i>	81
4. Problems associated with erythropoietin receptor determination on tumor cells <i>A. Österborg</i>	103
5. Definition, classification and characterization of anemia in cancer <i>M. R. Nowrousian</i>	117
6. Pathophysiology of anemia in cancer <i>M. R. Nowrousian</i>	149
7. Prevalence and incidence of anemia and risk factors for anemia in patients with cancer <i>H. Ludwig</i>	189
8. Significance of anemia in cancer chemotherapy <i>M. R. Nowrousian</i>	207
9. Incidence and impact of anemia in radiation oncology <i>J. Dunst and M. Molls</i>	249
10. Relationship between hemoglobin levels and tumor oxygenation <i>P. Vaupel, A. Mayer and M. Höckel</i>	265

11. Tumor hypoxia and therapeutic resistance <i>P. Vaupel and M. Höckel</i>	283
12. Symptoms of anemia <i>R. Pirker</i>	307
13. Impact of anemia and red blood cell transfusion on organ function <i>M. R. Nowrousian</i>	317
14. Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients <i>Z. Butt and D. Cella</i>	369
15. When to use red blood cell transfusions in cancer patients with solid tumours? <i>J. K. Jacob and P. J. Barrett-Lee</i>	393
16. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations <i>W. Jelkmann</i>	407
17. Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin's lymphoma <i>A. Österborg</i>	433
18. rhEPO in anemic patients with solid tumors and chemotherapy – efficacy and safety <i>M. R. Nowrousian</i>	449
19. Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia <i>G. H. Lyman and J. Glaspy</i>	509
20. Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia <i>E. Hellström-Lindberg</i>	531
21. Prediction of response to rhEPO in the anemia of cancer <i>Y. Beguin and G. Van Straelen</i>	541
22. rhEPO in hematopoietic stem cell transplantation <i>G. Van Straelen and Y. Beguin</i>	583

23. Treatment of anemia with rhEPO in radiation oncology <i>J. Dunst</i>	615
24. Recombinant human erythropoietin in pediatric oncology <i>C. Hastings and J. Feusner</i>	635
25. rhEPO in surgical oncology <i>M. J. Fontaine and L. T. Goodnough</i>	663
26. Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy <i>L. T. Goodnough</i>	679
27. Are there risks for use of iron in cancer patients? <i>P. Gascón</i>	703
28. Metabolic and physiologic effects of rhEPO in anemic cancer patients <i>K. Lundholm and P. Daneryd</i>	713
29. Effects of rhEPO on quality of life in anemic cancer patients <i>S. Chowdhury, J. F. Spicer, and P. G. Harper</i>	729
30. Thrombosis during therapy with erythropoiesis stimulating agents in cancer <i>J. Glaspy</i>	745
31. The effect of rhEPO on survival in anemic cancer patients <i>T. J. Littlewood</i>	759
32. <i>From bench to bedside: Neuroprotective effects of erythropoietin</i> <i>H. Ehrenreich and C. Bartels</i>	771
33. rhEPO in patients with anemia and congestive heart failure <i>D. S. Silverberg, D. Wexler, A. Iaina, S. Steinbruch, Y. Wollman, and D. Schwartz</i>	793
34. Cost-effectiveness of treating cancer anaemia <i>P. Cornes</i>	813
<i>Addendum</i>	851
<i>Index</i>	853